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Effective and safe treatments are required to relieve symptoms and improve the 
health-related quality of life of the millions of individuals who suffer from allergic 
symptoms1).  Oral antihistamines represent a mainstay of treatment because of their potent 
inhibition of the allergic response.  However, many antihistamines are associated with 
central nervous system (CNS) effects because of their lack of exclusive selectivity for the 
H1-receptor and their capacity to penetrate the blood-brain barrier (BBB)
2).  Sedation and 
psychomotor impairment associated with antihistamines can have serious safety 
implications.  The performance of everyday activities, such as car driving, in addition to 
tasks that require high levels of concentration, can be impaired after the administration of 
some antihistamines, with subsequent potentially serious, even fatal, consequences3).  It is 
accepted that older-generation antihistamines have sedative and impairing effects at 
recommended doses, which prompted the development of newer agents devoid of such 
effects.  However, newer-generation antihistamines are associated with divergent sedative 
profiles, so there remains a need to establish reliable and sensitive tests to evaluate this 
property2). 
This study was once reported as a work in progress and this time the complete 
results are reported here.  This study employed a variety of tests to examine their relative 
sensitivity and to establish the sedative profiles of three antihistamines – hydroxyzine 
(HYD; verum control), cetirizine (CET) and fexofenadine (FEX) – compared with placebo. 
Written informed consent was obtained from all study participants.  Study subjects were 
assessed in terms of: How sleepy they felt and how their performance was objectively 
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impaired using a series of laboratory tests (Study 1).  How their performance was impaired 
in a ‘real-life’ scenario, using a car driving test (Study 2).  The extent to which 
antihistamines bound to cerebral H1 - receptors using positron emission tomography (PET) 
(Study 3).  Studies 1 and 2 were conducted at CYRIC, Tohoku University. 
 
Materials and Methods 
Study 1: A total of 20 healthy adults males (mean age 23.1 ± 2.8 years) were 
recruited into this double-blind, placebo- and verum-controlled study. Subjects were 
randomized to receive FEX 120 mg, CET 20 mg, HYD 30 mg and placebo in a crossover 
fashion.  Subjective sleepiness was assessed using the Stanford Sleepiness Scale (SSS).  
This test was performed before and at 90 minutes after study drugs were administered, at 
which point visual cognitive function tests were also performed.  The visual cognitive 
function tests were analyzed using two variables: (1) reaction time (RT) and (2) correct 
answer rate (AR).  Both RT and AR were obtained for each subject who each performed a 
series of six tests. 
In the first test (choice reaction time: CRT), subjects were presented with an image 
to the left or right of a screen and were asked to respond by pressing the left-hand button if 
the image was on the right, and vice versa. Similar to the CRT, the simple reaction time test 
(SRT) involved the random presentation of images on the screen, to which the subject was 
asked respond by pressing the right-hand button as quickly as possible.  The third test, 
comprising four different subtests, was a visual discrimination task (VDT).  A total of 120 
images were presented with different exposure durations such as 3, 5, 7 or 20 msec and 
subjects were asked to respond only when figures, not letters were presented.  
Study 2: A total of 18 healthy adults males (mean age 23.4 ± 1.6 years) were 
recruited into this double-blind, placebo- and verum-controlled crossover study.  Each 
subject was administered FEX 120 mg, HYD 30 mg (verum control) and placebo and asked 
to perform a series of car braking tests using a system provided by Prof. Hindmarch 
(Human Psychopharmacology Research Unit, Surrey Univ., UK) with agreement of his 
group.  Subjects were asked to press a brake pedal when a light on the bonnet was lit, a 
process which occurred 25 times at random intervals during each test.  The brake reaction 
time (BRT) and subjective sleepiness were measured for each individual during each test. 
Tests were performed before and at 90 and 240 minutes after administration.  During each 
test, subjects inserted an earphone to enable them to talk on a mobile phone.  The four test 
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driving conditions for BRT were when:  
1) Not talking on mobile phone while driving,  
2) Driving and answering simple arithmetic questions on the mobile phone,  
3) Driving and answering complex arithmetic questions on the mobile phone,  
4) Driving and answering questions on a specific theme (such as a favorite movie). 
 
Study 3: Eleven healthy males (mean age 23.1 ± 2.8 years) underwent brain 
positron emission tomography (PET) after randomization to receive either FEX 120 mg or 
CET 20 mg.  Dynamic scanning of each subject was performed for 90 minutes, starting at 
90 minutes after drug administration (corresponding to the Tmax of the agents), at which 
point subjects were also administered intravenous 11C-doxepin, a selective radioligand for 
the H1-receptor.  To calculate the H1-receptor occupancy (H1RO) of each drug, the binding 
potential (BP; Bmax/KD) of each agent in each region of interest (ROI) in the brain was 
calculated, as described elsewhere4,5).  BP images were created, from which H1RO was 
calculated for the frontal cortex, anterior cingulate gyrus, temporal cortex, parietal cortex 
and occipital cortex, using the mean BP values of placebo condition obtained in other 
additional subjects.  The H1ROs of FEX and CET were calculated using the following 
equation: 
H1RO = [(mean BP of control – mean BP with each drug)/mean BP of control] x 100. 
 
Results 
Study 1: As for the change in mean RT before and after medication (Figure 1), in 
five of six cognitive tasks, HYD was significantly more impairing than placebo.  FEX did 
not differ significantly from placebo in terms of impairment.  CET was significantly more 
impairing than FEX in CRT test (p=0.008).  The results of AR showed similar tendency.  
As for subjective sleepiness, FEX resulted in indistinguishable sleepiness compared with 
placebo.  Trends towards increased sleepiness with HYD and CET compared with placebo 
and FEX were observed, although these did not reach statistical significance. In addition, 
increased sedation was reported with CET compared with FEX in one task. 
Study 2: Significant sedation was observed with HYD at 90 and 240 minutes after 
administration, as assessed by the SSS (p=0.017 and p=0.003 versus placebo, respectively).  
No significant subjective sedation was observed with FEX compared with placebo (Figure 
2) (p>0.05).  At 240 minutes, HYD significantly prolonged BRT compared with 
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placebo under all test conditions except when driving but not talking on the mobile phone 
(p<0.05).  At 240 minutes, HYD prolonged BRT significantly compared with FEX when 
driving and performing simple arithmetic, and when driving and talking on a mobile phone 
(p<0.05).  Interestingly, prolongation in BRT seems more influenced by a dual task 
situation caused by cellular phone talks during driving than an administration of HYD, a 
sedative drug (Figure 2). 
Study 3: Sample PET scans of an individual subject are shown (Figure 3).  The 
brighter the region, the greater the concentration of free H1-receptors to which 
11C-doxepin 
molecules bind, or the lower the concentration of antihistamine penetrating BBB.  CET 
binds more readily to cerebral H1-receptors than either FEX or placebo, as evidenced both 
from the PET images and the H1RO calculations.  CET was observed to occupy 
H1-receptors in the cerebral cortex (20 to 30%).  In contrast, FEX occupied receptors in the 
cerebral cortex to lesser extent (0 to 5.6%).  
 
Discussion 
The twin purposes of performing and comparing the three different studies were to 
evaluate the relative sensitivities of each test to detect impairment by antihistamines and to 
explore the impairment profiles of FEX, CET and HYD.  The results of Study 1 
demonstrate that evaluation of subjective sleepiness using the SSS sometimes cannot 
distinguish clearly between the known sedative effects of the positive control, HYD, and 
placebo. Although the results of the SSS suggest a trend in increasing sleepiness: 
FEX=placebo< CET< HYD, these differences were not statistically significant. However, 
this relationship was confirmed by the results of the objective psychomotor tests performed 
in the laboratory in Study 1.  Then, it seems that objective psychomotor tests are more 
sensitive than measurement of subjecitve sleepiness. 
Study 2 was conducted to determine if the results of an objective ‘real-life’ test of 
impairment could “mirror” the results obtained in the laboratory and to assess patients’ 
reactions to performing dual tasks of varying difficulty. An additive impairing effect was 
observed when subjects performed dual tasks simultaneously following administration of 
HYD, which was not observed after administration of FEX. Since the dorsolateral 
prefrontal cortex, which is postulated to be involved when performing the multiple tasks 
demanded of the driving study (Study 2) simultaneously, is relatively abundant in histamine 
H1-receptors, this brain region is likely to be affected strongly by antihistamines that can 
penetrate the BBB6).  The results suggest that an experiment in real-life situation is less 
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sensitive than that done in laboratory situation.  
The results of Studies 1 and 2 imply that HYD crosses the BBB, binds to receptors 
in the cerebral cortex, thus resulting in impairment, whereas FEX does not.  Study 3 
confirmed that FEX does not penetrate the BBB, in contrast to CET, which had an H1RO 
rate of around 20 to 30% depending on the ROI.  The PET results suggest that the 
impairing properties of CET demonstrated in some psychomotor tests in Study 1 could be 
attributed to the binding of the antihistamine to cerebral H1-receptors. 
 
Conclusions 
These studies suggest that sensitivities of the methods are as follows: [BRT study in 
real-life situation]= [subjective sleepiness]< [psychomotor study in a laboratory]< [H1RO 
measurement with PET].  These studies also suggest that antihistamines increase in their 
impairing potential in the following order: FEX< CET< HYD.  Further, FEX has a similar 
sedative profile to placebo.  A multidimensional testing system is required to establish the 
relative impairment profiles of antihistamines, since a single test cannot reveal H1RO, how 
sedated patients feel and how well they perform a diverse range of tasks.  Further testing is 
required of all newer-generation agents to confirm their relative propensity to cross the 
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Figure 1.  Change in the mean reaction time before and after medication. 



























Figure 2.  Results of BRT measurement in car driving study. *statistically significant examined by 
































Figure 3.  PET scans of brain regions after administration of CET, FEX and placebo. Images after 
administration of CET show lower binding of 11C-doxepin compared to tother conditions (FEX and placebo) 
(ref.7).  
